Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567931 · ClinicalTrials.gov registry record · Phase 1
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT00567931 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00567931, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Biological therapies, such as 1-methyl-D-tryptophan, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stimulating the immune system.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG 1-methyl-d-tryptophan
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567931
The ClinicalTrials.gov registry entry for NCT00567931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (90% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00567931 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Virginia.
Frequently Asked Questions
What is clinical trial NCT00567931 about?
NCT00567931 is a clinical study titled "1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery". This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Biological therapies, such as 1-methyl-D-tryptophan, may stop the growth of tumor cells by blocking some of the en...
What is the current status of trial NCT00567931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2007-10. Estimated completion is 2012-09.
What conditions does trial NCT00567931 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00567931?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), 1-methyl-d-tryptophan (DRUG).
Who is sponsoring clinical trial NCT00567931?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567931 being conducted?
This trial has 2 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.